Louisiana State Employees Retirement System raised its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 1.2% during the second quarter, Holdings Channel reports. The fund owned 24,600 shares of the life sciences company’s stock after buying an additional 300 shares during the period. Louisiana State Employees Retirement System’s holdings in Integra LifeSciences Holdings Corporation were worth $1,341,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of IART. Koch Industries Inc. acquired a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter valued at $250,000. First Mercantile Trust Co. acquired a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter valued at $279,000. Columbus Circle Investors acquired a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter valued at $18,875,000. Wells Fargo & Company MN raised its position in shares of Integra LifeSciences Holdings Corporation by 18.0% in the first quarter. Wells Fargo & Company MN now owns 2,467,892 shares of the life sciences company’s stock valued at $103,972,000 after buying an additional 375,857 shares during the last quarter. Finally, American Century Companies Inc. raised its position in shares of Integra LifeSciences Holdings Corporation by 105.9% in the first quarter. American Century Companies Inc. now owns 196,830 shares of the life sciences company’s stock valued at $8,292,000 after buying an additional 101,244 shares during the last quarter. Institutional investors own 89.70% of the company’s stock.
Shares of Integra LifeSciences Holdings Corporation (NASDAQ IART) opened at 55.04 on Friday. The firm has a market capitalization of $4.16 billion, a PE ratio of 65.52 and a beta of 0.75. The firm has a 50-day moving average price of $53.45 and a 200-day moving average price of $46.43. Integra LifeSciences Holdings Corporation has a 1-year low of $37.71 and a 1-year high of $56.42.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, April 26th. The life sciences company reported $0.39 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by $0.01. Integra LifeSciences Holdings Corporation had a return on equity of 16.67% and a net margin of 6.66%. The business had revenue of $258.60 million for the quarter, compared to analysts’ expectations of $254.19 million. During the same period last year, the company posted $0.38 earnings per share. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. On average, analysts forecast that Integra LifeSciences Holdings Corporation will post $1.92 EPS for the current fiscal year.
IART has been the subject of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research report on Monday, July 10th. ValuEngine lowered Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Jefferies Group LLC raised their price target on Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 price target on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Monday, May 15th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $48.00 price target (up from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, May 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $52.41.
In related news, Director Stuart Essig sold 140,000 shares of the company’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $48.01, for a total transaction of $6,721,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Glenn Coleman sold 13,865 shares of the company’s stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $45.91, for a total transaction of $636,542.15. Following the sale, the vice president now directly owns 18,519 shares of the company’s stock, valued at $850,207.29. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 304,523 shares of company stock valued at $14,812,988. 21.40% of the stock is owned by corporate insiders.
Integra LifeSciences Holdings Corporation Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).
Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
